NASDAQ · POM
Healthcare · Medical - Pharmaceuticals
$0.97
Up+$0.05 (+4.66%)
Updated Aug 14, 2026, 12:09 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
POM does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning POM.
POM research
Company profile and research snapshot.
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Feb 4, 2026
POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced a strategic initiative to deepen the integration of its
Benzinga · Feb 2, 2026
POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced that it has received a written notification (the "Deficiency
prnewswire.com · Dec 3, 2025
GUANGZHOU, China , Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its unaudited financial results for the six months ended June 30, 2025. Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "The first half of fiscal year 2025 reflected our deliberate and disciplined efforts to balance business expansion with operational rigor.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning POM.
No results
No recent SID articles mention POM.
